Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tetra(Imidazole)Diaquacopper (Ii) is a copper(II) coordination complex featuring four imidazole ligands and two aqua (water) ligands. This small molecule is primarily a subject of academic research, exploring its chemical properties and potential biological activities. Studies on similar copper(II)-imidazole complexes have indicated a range of biological effects, including antimicrobial, antifungal, and antitumor properties. Its potential mechanisms of action involve interactions with DNA, induction of mitochondrial dysfunction leading to apoptosis, and modulation of reactive oxygen species. While not a clinically approved pharmaceutical drug, its demonstrated biological activities suggest potential for development as a therapeutic agent.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tetra(Imidazole)Diaquacopper (Ii).